title: Bioequivalence of Jusline following subcutaneous administration in healthy subjects.
abstract: OBJECTIVE
  The aim of the current work is to evaluate the pharmacokinetic and pharmacodynamic profile of a new human insulin preparation (jusline) following subcutaneous administration in healthy subjects, and to compare this profile with Humulin insulin.
  
  
  METHODS
  20 healthy male subjects received a single dose of 0.2 U/kg of test (Jusline) or reference insulin (Humulin) during an euglycemic clamp keeping blood sugar constant (90 +/- 5 mg/dl) by changing the glucose infusion rate. Pharmacokinetic and pharmacodynamic measurements were taken from blood measurements of glucose, insulin, and C-peptide levels for tested insulin formulations.
  
  
  RESULTS
  The mean values of the individual AUC ratios were well within the 90% confidence interval (100.5% for Regular, 101.9% for NPH, and 100.0% for Premixed Regular/NPH (30/70)). Similarly, Cmax and tmax were within the bioequivalence limit (80 - 125%). The maximum GIR were 10.20 mg/kg/min and 9.72 mg/kg/min for Jusline Regular and Humulin Regular, respectively. The maximum GIR were 7.09 mg/kg/min and 7.91 mg/kg/min for Jusline NPH and Humulin NPH, respectively. The maximum GIR and tGIRmax were 6.39 mg/kg/min and 6.63 mg/kg/ min for Jusline Premixed Regular/NPH (30/70) and Humulin Premixed Regular/NPH (30/70), respectively. Both insulin products produced similar suppression of endogenous C-peptide level (-29.76% to -50.22%).
  
  
  CONCLUSIONS
  The present study demonstrated that after subcutaneous administration, there are no significant differences between Jusline and Humulin to promote peripheral glucose uptake.
authors.affiliation: Department of Medicine, College of Medicine, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
authors.forename: K A
authors.initials: KA
authors.lastname: Al-Rubeaan
authors.forename: N M
authors.initials: NM
authors.lastname: Al-Daghri
authors.forename: K M
authors.initials: KM
authors.lastname: Alkharfy
authors.forename: O S
authors.initials: OS
authors.lastname: Al-Attas
authors.forename: F S
authors.initials: FS
authors.lastname: Hanif
authors.forename: N S
authors.initials: NS
authors.lastname: Metias
authors.forename: S L B
authors.initials: SL
authors.lastname: Sabico
mesh_terms: D000293:Adolescent; D000328:Adult; D019540:Area Under Curve; D001786:Blood Glucose / Q000187:drug effects*; D002096:C-Peptide / Q000097:blood / Q000187:drug effects; D004311:Double-Blind Method; D015309:Glucose Clamp Technique; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D007279:Injections, Subcutaneous; D007328:Insulin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D007336:Insulin, Isophane / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008297:Male; D013810:Therapeutic Equivalency
chemical_list: D001786:Blood Glucose; D002096:C-Peptide; D007004:Hypoglycemic Agents; D007328:Insulin; D007336:Insulin, Isophane